抑酸药物的种类及研究进展
The Kinds of Acid Suppression Drugs and Research Progress
摘要: 近年来，随着饮食结构的多样化和生活方式的明显改变，酸相关性疾病如胃食管反流病、胃溃疡、十二指肠溃疡等疾病的发病率逐年升高，其治疗药物多种多样，疗效及其副作用各异，现将各种抑酸药物的作用机制、治疗效果、优缺点、研究现状等进行归类总结，意在为临床医生提供更优的抑酸药物选择方案，从而更有效地治疗酸相关疾病。
Abstract: In recent years, with the diversification of diet and lifestyle changes obviously, the incidence of acid related diseases such as gastroesophageal reflux disease, gastric ulcer, duodenal ulcer increased year by year. The drugs varied, curative effect and side effects vary. Now the mechanism of action of various acid suppression drugs, treatment effects, advantages and disadvantages, current research status and so on are classified and summarized, to provide better acid suppression drugs for clinical doctors options, thus more effective in the treatment of acid related diseases.
文章引用：丁晨露, 史丽萍, 张健. 抑酸药物的种类及研究进展[J]. 临床医学进展, 2022, 12(12): 11954-11961. https://doi.org/10.12677/ACM.2022.12121722

参考文献

[1] Engevik, A.C., Kaji, I. and Goldenring, J.R. (2020) The Physiology of the Gastric Parietal Cell. Physiological Reviews, 100, 573-602. [Google Scholar] [CrossRef] [PubMed]
[2] Shin, J.M., Munson, K. and Sachs, G. (2011) Gastric H+, K+-ATPase. Comprehensive Physiology, 1, 2141-2153. [Google Scholar] [CrossRef] [PubMed]
[3] Nugent, C.C., Falkson, S.R. and Terrell, J.M. (2022) H2 Blockers. StatPearls. Treasure Island.
[4] 张石革, 宗怡. 组胺H2受体拮抗剂的进展与合理应用[J]. 中国全科医学, 2002, 5(11): 913-916.
[5] Brett, M.F. (2018) Management of Gastroesophageal Reflux Disease in Adults: A Pharmacist’s Perspective. Integrated Pharmacy Research and Practice, 7, 41-52. [Google Scholar] [CrossRef] 
[6] 赵斌, 解学超, 王振华, 魏开惠. 组胺H2受体拮抗剂不良反应的流行病学特点研究[J]. 中国医院药学杂志, 2014, 34(8): 675-678.
[7] Histamine Type-2 Receptor Antagonists (H2 Blockers). In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases, Bethes-da.
[8] Martínez, C., Albet, C., Agúndez, J.A., Herrero, E., Carrillo, J.A., Márquez, M., Benítez, J. and Ortiz, J.A. (1999) Comparative in Vitro and in Vivo Inhibition of Cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-Receptor Antagonists. Clinical Pharmacology & Therapeutics, 65, 369-376. [Google Scholar] [CrossRef] 
[9] El Rouby, N., Lima, J.J. and Johnson, J.A. (2018) Proton Pump Inhibitors: from CYP2C19 Pharmacogenetics to Precision Medicine. Expert Opinion on Drug Metabolism & Toxicology, 14, 447-460. [Google Scholar] [CrossRef] [PubMed]
[10] 张培培, 王永庆, 龚晓健. 质子泵抑制剂研究新进展[J]. 药学进展, 2011, 35(11): 487-495.
[11] Shin, J.M., Munson, K, Vagin, O. and Sachs, G. (2011) Erratum: The Gastric HK-ATPase: Structure, Function, and Inhibition. Pflügers Archiv—European Journal of Physiology, 461, 399-399. [Google Scholar] [CrossRef] 
[12] Salas, M., Ward, A. and Caro, J. (2002) Are Proton Pump Inhib-itors the First Choice for Acute Treatment of Gastric Ulcers? A Meta Analysis of Randomized Clinical Trials. BMC Gastroenterology, 2, Article No. 17. [Google Scholar] [CrossRef] 
[13] van Pinxteren, B., Numans, M.E., Bonis, P.A. and Lau, J. (2003) Short-Term Treatment with Proton Pump Inhibitors, H2-Receptor Antagonists and Prokinetics for Gastro-Oesophageal Reflux Disease-Like Symptoms and Endoscopy Negative Reflux Disease. Cochrane Database of Systematic Reviews, 5, Article ID: CD002095. [Google Scholar] [CrossRef] 
[14] Zhang, Y.-S., Li, Q., He, B.-S., Liu, R. and Li, Z.-J. (2015) Proton Pump Inhibitors Therapy vs H2 Receptor Antagonists Therapy for Upper Gastrointestinal Bleeding after Endoscopy: A Meta-Analysis. World Journal of Gastroenterology, 21, 6341-6351. [Google Scholar] [CrossRef] [PubMed]
[15] 袁培杰, 李夏平, 李乐谦, 刘伟, 黄梅芳, 熊婧. 高剂量二联疗法与经典四联疗法根除幽门螺杆菌的疗效对比[J]. 现代消化及介入诊疗, 2021, 26(6): 681-684.
[16] 张丽君, 吕栋. 雷贝拉唑三联及四联疗法根除Hp感染消化性溃疡[J]. 中国继续医学教育, 2019, 11(28): 139-141.
[17] Shin, J.M. and Sachs, G. (2008) Pharmacology of Proton Pump Inhibitors. Current Gastroenterology Reports, 10, Article No. 528. [Google Scholar] [CrossRef] [PubMed]
[18] 王世鑫. 抑酸剂的现状与展望[J]. 中国消化内镜, 2008, 2(4): 41-46.
[19] 单清, 孙安修. 质子泵抑制剂预防性应用专家共识(2018) [J]. 中国医师杂志, 2018, 20(12): 1775-1781.
[20] 王焱, 刘英, 李芳, 张国领. 质子泵抑制剂的临床应用研究进展[J]. 中华保健医学杂志, 2021, 23(4): 415-416, 419. [Google Scholar] [CrossRef] 
[21] Bavishi, C. and DuPont, H.L. (2011) Systematic Re-view: The Use of Proton Pump Inhibitors and Increased Susceptibility to Enteric Infection. Alimentary Pharmacology & Therapeutics, 34, 1269-1281. [Google Scholar] [CrossRef] [PubMed]
[22] Mcdonald, E.G., Milligan, J., Frenette, C. and Lee, T.C. (2015) Continuous Proton Pump Inhibitor Therapy and the Associated Risk of Recurrent Clostridium difficile Infection. JAMA Internal Medicine, 175, 784-791. [Google Scholar] [CrossRef] [PubMed]
[23] Yang, Y.X, Lewis, J.D., Epstein, S. and Metz, D.C. (2006) Long-Term Proton Pump Inhibitor Therapy and Risk of Hip Fracture. JAMA: The Journal of the American Medical Association, 296, 2947-2953. [Google Scholar] [CrossRef] [PubMed]
[24] Echizen, H. (2016) The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations. Clinical Pharmacokinetics, 55, 409-418. [Google Scholar] [CrossRef] [PubMed]
[25] Inatomi, N., Matsukawa, J., Sakurai, Y. and Otake, K. (2016) Potassium-Competitive Acid Blockers: Advanced Therapeutic Option for Acid-Related Diseases. Pharmacology & Therapeutics, 168, 12-22. [Google Scholar] [CrossRef] [PubMed]
[26] Sakurai, Y., Nishimura, A., Kennedy, G., et al. (2015) Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/Non-Japanese Subjects. Clinical and Translational Gastroenterology, 6, e94. [Google Scholar] [CrossRef] [PubMed]
[27] Herszényi, L., Bakucz, T., Barabás, L. and Tulassay, Z. (2019) Pharma-cological Approach to Gastric Acid Suppression: Past, Present, and Future. Digestive Diseases, 38, 104-111. [Google Scholar] [CrossRef] [PubMed]
[28] Ashida, K., Sakurai, Y., Hori, T., et al. (2016) Randomised Clinical Trial: Vonoprazan, a Novel Potassium-Competitive Acid Blocker, vs. Lansoprazole for the Healing of Erosive Oesophagitis. Alimentary Pharmacology & Therapeutics, 43, 240-251. [Google Scholar] [CrossRef] [PubMed]
[29] Kawai, T., Ashida, K., Mizokami, Y., et al. (2014) Tu1055 TAK-438 versus Lansoprazole 15 mg for Secondary Prevention of Peptic Ulcers Associated with Low-Dose Aspirin Therapy: Results of a Phase 3 Trial. Gastroenterology, 14, S-739. [Google Scholar] [CrossRef] 
[30] Murakami, K., Sakurai, Y., Shiino, M., et al. (2016) Vonoprazan, a Novel Potassium-Competitive Acid Blocker, as a Component of First-Line and Second-Line Triple Therapy for Helicobacter pylori Eradication: A Phase III, Randomised, Double-Blind Study. Gut, 65, 1439-1446. [Google Scholar] [CrossRef] [PubMed]
[31] Kiyotoki, S., Nishikawa, J. and Sakaida, I. (2020) Efficacy of Vonoprazan for Helicobacter pylori Eradication. Internal Medicine, 59, 153-161. [Google Scholar] [CrossRef] [PubMed]
[32] Tanabe, H., Yoshino, K., Ando, K., et al. (2018) Vonoprazan-Based Triple Therapy Is Non-Inferior to Susceptibility-Guided Proton Pump Inhibitor-Based Triple Therapy for Helicobacter pylori Eradication. Annals of Clinical Microbiology and Antimicrobials, 17, Article No. 29. [Google Scholar] [CrossRef] [PubMed]
[33] Miftahussurur, M., Putra, B.P. and Yamaoka, Y. (2020) The Po-tential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy. Pharmaceuticals, 13, Article No. 276. [Google Scholar] [CrossRef] [PubMed]
[34] Kambara, H., Hosohata, K., Nakatsuji, T., et al. (2020) Safety Profile of Vonoprazan Compared with Proton Pump Inhibitors: Insight from a Pharmacovigilance Study. Die Pharmazie—An International Journal of Pharmaceutical Sciences, 75, 527-530.

为你推荐